Ibrutinib (PCI-32765) in Waldenstrom's Macroglobulinemia

Completed · Phase 2

Conditions studied: Waldenstrom's Macroglobulinemia

In brief

This research study is a Phase II clinical trial. Phase II clinical trials test the effectiveness of an investigational drug, PCI-32765, to learn whether PCI-32765 works in treating a specific cancer. "Investigational" means that PCI-32765 is still being studied and that research doctors are trying to find out more about it-such as the safest dose to use, the side effects it may cause, and if PCI-32765 is effective for treating different types of cancer. It also means that the FDA has not yet approved PCI-32765 for use in patients, including people with Waldenstrom's Macroglobulinemia. PCI-32765 is a newly discovered drug that is being developed as an anti-cancer agent. PCI-32765 is a Bruton's tyrosine kinase (Btk) inhibitor drug which interrupts B cell receptor (BCR) signaling in lymphomas by selectively and irreversibly binding to the Btk protein, which then results in malignant cell death. This drug has been used in laboratory experiments and other research studies in B-cell malignancies and information from those other research studies suggests that PCI-32765 may be a treatment strategy for B-cell malignancies, including Waldenstrom's Macroglobulinemia. In this research study, the investigators are testing the safety and efficacy of PCI-32765 as a treatment option for relapsed or refractory Waldenstrom's Macroglobulinemia.

Key facts

Study ID

NCT01614821

Run by

Dana-Farber Cancer Institute

People needed

63

Starts

2012-05-01

Expected to finish

2018-09-15

Last updated by the study team

2020-01-21

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Clinicopathological diagnosis of Waldenstrom's Macroglobulinemia
• Measurable disease
• Have received at least one prior therapy for WM therapies
• Disease free of prior malignancies
• Able to adhere to study visit schedule and other protocol requirement

You may not qualify if…

• Pregnant or breastfeeding
• Any other serious medical condition
• Concurrent use of other anti-cancer agents or treatments
• Prior exposure to PCI-32765
• Known CNS lymphoma
• Significant cardiovascular disease
• Any disease affecting gastrointestinal function

Where it is running

• Stanford University — Palo Alto, California, United States
• Brigham and Women's Hospital — Boston, Massachusetts, United States
• Dana-Farber Cancer Institute — Boston, Massachusetts, United States
• Memorial Sloan-Kettering Cancer Center — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.